- Adverse Reaction
- Incidence (N=40)
TROGARZO® is generally well tolerated, with a low incidence of adverse reactions.
* Includes pooled terms “rash”, “rash erythematous”, “rash generalized”, “rash macular”, “rash maculopapular”, and “rash papular”.
TROGARZO® IS INCLUDED IN THE DHHS GUIDELINES FOR MANAGING TREATMENT EXPERIENCED HIV-1 PATIENTS
DEFINE FAILURE: HIV RNA ≥ 200 copies/mL
Persistent HIV RNA ≥ 200 copies/mL is considered virologic failure, and is associated with accumulation of drug-resistance mutations.
BE PROACTIVE: MODIFY AS SOON AS POSSIBLE
When resistance mutations compromise a regimen, it should be modified as soon as possible to avoid progressive accumulation of resistance mutations.
Virologic responses to new regimens are greater in patients with lower HIV RNA levels and/or higher CD4 cell counts.
Thus, a change is best done before viremia worsens or CD4 count declines.
CHOOSE A FULLY ACTIVE REGIMEN
A new regimen should include at least two, and preferably three, fully active agents. A fully active agent is one that is expected to have uncompromised activity on the basis of the patient’s ART history and his or her current and past drug-resistance test results.
CONSIDER A NEWER MOA
The availability of newer ART, including those with new mechanisms of action, makes it possible to suppress HIV RNA to <50 copies/mL in most patients.